CNR President Maria Chiara Carrozza visits HT
Today CNR President Maria Chiara Carrozza visited Human Technopole headquarters together with a delegation of department and institute directors of the National Research Council. HT Director Iain Mattaj and HT President Marco Simoni were joined at the meeting by representatives of the institute’s research areas who gave President Carrozza a tour of Human Technopole’s first laboratory spaces.
“We are very pleased to welcome to Palazzo Italia the newly appointed CNR President Maria Chiara Carrozza. Since its very early stages, Human Technopole has initiated a dialogue with representatives of the national scientific community to build a collaborative network and bring added value to an already thriving research ecosystem. We share with CNR our commitment to scientific excellence, an open and international approach and our goal of training the next generation of scientists” stated prof. Mattaj.
President Carrozza underlined, “I am happy to have met, together with the directors of Cnr, the top management and colleagues of Human Technopole and to have visited their headquarters. It was an informal, simple and friendly visit, in the spirit of a meeting between researchers, but important to prepare ourselves for the challenges we will face post-pandemic, starting from ecological transition, digital transformation and health. Challenges in which the contribution of research, and particularly biomedical research, is fundamental “.
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.